Login to Your Account

Clinic Roundup

Monday, July 18, 2011
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., is recruiting for a Phase II trial evaluating VGX-3100, its investigational SynCon DNA vaccine, in 148 subjects with high grade cervical intraepithelial neoplasia 2/3 or 3.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription